Patents by Inventor Stephanie Royer JOO

Stephanie Royer JOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
    Publication number: 20230321102
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. GDC-6036) and an PI3K-inhibitor (e.g. inavolisib) and methods of using such combination therapies.
    Type: Application
    Filed: April 4, 2023
    Publication date: October 12, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Zhen SHI, Chunyan SONG, Neekesh Vijay DHARIA, Stephanie Royer JOO
  • COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER
    Publication number: 20230310455
    Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
    Type: Application
    Filed: June 9, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Lee Schutzman, Chunyan Song, Kyung Wha Song, Eirini Thanopoulou, Simon Peter Warburton, Anwesha Dey, Stephanie Royer Joo
  • METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A EGFR-INHIBITOR FOR TREATING SOLID TUMORS
    Publication number: 20220193077
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1) and an EGFR-inhibitor and methods of using such combination therapies.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 23, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Anne EVANGELISTA, Stephanie Royer JOO, Ting-Kun Mark LIN, Sandhya Vinayak MANDLEKAR, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN
  • METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORS
    Publication number: 20220152030
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar, Stuart G. Lutzker
  • METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCER
    Publication number: 20220152029
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR